A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus ...
Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...
Event: LD Micro Main Event XIX Date: Tuesday, October 21st Time: 11:30 ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential. On October 3, Alto ...
Ingelheim: Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for JASCAYD ...
Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE ...
Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...
The time to onset of action for the treatment of plaque psoriasis was fastest with the interleukin-17 inhibitor bimekizumab, with an estimated effect time of 5.9 weeks. Interleukin (IL)-17 inhibitors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback